Condition: Diffuse Large B Cell Lymphoma · Primary Mediastinal Large B Cell Lymphoma · Large B-cell Lymphoma · Sponsor: Pell Bio-Med Technology Co., Ltd.
This is a multiple center, non-randomized, open-label, phase 1/2 study. The primary objective of Phase 1 is to evaluate the safety of PL001 and find the recommended Phase 2 dose (RP2D). The objective of Phase 2 is to evaluate the safety and efficacy of CD19 CAR-T(known as PL001).
This description comes directly from the study's public registry record.
Cherry Lo, MSC · 886-2-8791-1789 · cherry.lo@pellbmt.com
Always discuss trial participation with your own doctor first.
| National Taiwan University Hospital | Taipei, Taiwan, Taiwan | Recruiting |
| Kaohsiung Medical University Chung-Ho Memorial Hospital | Kaohsiung City, Taiwan | Recruiting |
| Chi Mei Medical Center | Tainan, Taiwan | Not Yet Recruiting |
| Taipei Medical University - Taipei Medical University Hospital | Taipei, Taiwan | Recruiting |
| Taipei Veterans General Hospital | Taipei, Taiwan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05326243